GlassScriptPhysician profile
Jerry Kong
NPI 1720433345
$9,785.17
in general payments reported to CMS, 2019-2025
45 companies · $4,505 in 2025
The $4,505 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.28 · 2020: $620 · 2021: $358 · 2023: $386 · 2024: $3,818 · 2025: $4,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,708.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,783.70 | 2023-2025 | |
| Abbvie INC. | $1,718.69 | 2023-2025 | |
| Amgen INC. | $694.72 | 2020-2025 | Uplizna, Aimovig |
| Tonix Medicines, INC. | $653.46 | 2024-2025 | Zembrace Symtouch |
| Lundbeck LLC | $556.28 | 2020-2025 | Vyepti |
| Currax Pharmaceuticals LLC | $493.93 | 2024-2025 | Contrave, Onzetra Xsail |
| Teva Pharmaceuticals USA, INC. | $411.48 | 2020-2025 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $375.79 | 2020-2025 | Emgality, Reyvow, Zepbound |
| Novo Nordisk INC | $338.47 | 2023-2025 | Wegovy, Ozempic |
| Axsome Therapeutics, INC. | $288.30 | 2025 | Symbravo |
| Tg Therapeutics, INC. | $204.91 | 2024-2025 | |
| Ucb, INC. | $201.45 | 2023-2025 | Nayzilam, Rystiggo, Fintepla |
| Eisai INC. | $187.07 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $183.96 | 2024-2025 | Ingrezza |
| Allergan, INC. | $178.80 | 2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $165.19 | 2024-2025 | Qutenza |
| Jazz Pharmaceuticals INC. | $157.77 | 2024-2025 | |
| Impel Pharmaceuticals LLC | $119.28 | 2024-2025 | Trudhesa |
| Scilex Pharmaceuticals INC. | $111.26 | 2023-2025 | Elyxyb |
| Glaxosmithkline, LLC. | $98.28 | 2019 | |
| Sk Life Science, INC. | $81.30 | 2024-2025 | |
| Upsher-Smith Laboratories LLC | $79.31 | 2020 | |
| Livanova USA, INC. | $73.18 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Impel Pharmaceuticals INC. | $68.24 | 2023 | Trudhesa |
| Genzyme Corporation | $58.14 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $46.85 | 2024 | Crexont, Rytary |
| Alexion Pharmaceuticals, INC. | $46.27 | 2024-2025 | Ultomiris |
| Neurelis, INC. | $38.79 | 2025 | Valtoco |
| Azurity Pharmaceuticals, INC. | $36.02 | 2023-2024 | Eprontia, Zonisade |
| Argenx US, INC. | $35.67 | 2025 | Vyvgart Hytrulo |
| Janssen Biotech, INC. | $32.60 | 2025 | |
| Emd Serono, INC. | $27.05 | 2024 | |
| Csl Behring | $25.43 | 2024 | Hizentra |
| Genentech USA, INC. | $25.16 | 2025 | Ocrevus Zunovo |
| Otsuka America Pharmaceutical, INC. | $25.11 | 2024 | Rexulti |
| Ani Pharmaceuticals, INC. | $21.25 | 2025 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $20.83 | 2025 | Xeomin, Ampyra, Inbrija |
| Vanda Pharmaceuticals INC. | $20.29 | 2025 | Ponvory |
| Acadia Pharmaceuticals INC | $18.66 | 2025 | Nuplazid |
| Zyla Life Sciences, INC. | $17.53 | 2020 | |
| Merck Sharp & Dohme LLC | $17.17 | 2024 | Welireg |
| Celgene Corporation | $17.03 | 2025 | Zeposia |
| Assertio Therapeutics, INC. | $15.66 | 2020 | |
| Biogen, INC. | $14.84 | 2024 | Vumerity, Tysabri |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$67,088.88 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Kong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.